DOCSLIB.ORG

New Prescription Meds You Should Know 2015 FDA Approvals

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
New Prescription Meds You Should Know 2015 FDA Approvals 4/19/16 2015 FDA Approvals • 45 novel drugs approved in 2015 • 16 of the 45 (36%) are First-in-Class approvals • 47% of drugs approved to treat rare or “orphan” New Prescription Meds diseases (< 200,000 Americans) You Should Know • 14 drugs (31%) were Fast Track approvals • Many other approvals for new formulations Sally Haack, PharmD http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM485053.pdf Drake University College of Pharmacy & Health Sciences April 19, 2016 Today’s Update Diabetes • Diabetes • Psychiatry • Cardiovascular • Hepatitis C • Respiratory • Miscellaneous 1 4/19/16 Insulin Glargine: Basaglar Insulin Glargine: Basaglar • Approved by FDA in December 2015 • Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc • Indication: basal insulin to control high blood glucose in type 1 or type 2 diabetes • Available in US starting December 2016 • Administration: subcutaneously once daily (U-100; 3 mL pen) www.basaglar.com Diabetes, Obesity and Metabolism 17:734-741, 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm477734.htm Insulin Glargine: Basaglar Insulin Glargine: Toujeo • Approved by FDA in February 2015; available in April 2015 • Sanofi – Aventis: makers of Lantus • Indication: basal insulin approved for adults with type 1 or type 2 diabetes • Available in a SoloStar pen; 300 units/mL – No conversion necessary between Lantus and Toujeo – Less volume per injection – Gradual release in a compact depot of insulin – different than Lantus; may lead to >24 hour duration of action Diabetes, Obesity and Metabolism 17:734-741, 2015. Insulin Glargine: Toujeo Insulin Glargine: Toujeo Mean HbA1c at 12 months: 7.62 (1.03)% in the Gla-300 group and 7.64 (1.21)% in the Gla-100 group Diabetes, Obesity and Metabolism 17:1142-1149. 2 4/19/16 Insulin Degludec: Tresiba Insulin Degludec: Tresiba • Approved by FDA in September 2015 • Novo-Nordisk • Indication: once-daily, long acting basal insulin approved to control blood sugar in adults with diabetes • Administration: subcutaneously via FlexPen • Available in U-200 and U-100 concentrations • U-200 ~ 600 units/pen; max of 160 units/dose • Ryzodeg 70/30 (insulin degludec/insulin aspart injection) Diabetes Care 35:2464–2471, 2012 Insulin Degludec: Tresiba Psychiatry Diabetes Care 36:2536–2542, 2013 Vraylar (cariprazine) Vraylar (cariprazine) • Approved by FDA in September 2015 • Allergan: Forest Laboratories • Indication: atypical antipsychotic for schizophrenia or bipolar mania • Administration: orally once daily {bipolar 3-6 mg daily; schizophrenia 1.5-6 mg daily} • Adverse drug reactions – EPS, akathisia • Drug interactions with other CYP3A4 inhibitors – Reduce Vraylar dose by half • Monitoring Schizophrenia Research 152 (2014) 450–457 3 4/19/16 Rexulti (brexpiprazole) Rexulti (brexpiprazole) • FDA approved in July 2015 • Otsuka America Pharmaceutical, Inc. • Indication: atypical antipsychotic for major depressive disorder or schizophrenia • Administration: orally once daily {MDD 0.5-3 mg daily; schizophrenia 1-4 mg daily} • Adverse drug reactions – Weight gain and akathisia • Drug interactions and monitoring J Clin Psychiatry 2015;76(9):1232–1240 Aristada (aripiprazole) Cardiovascular • FDA approved October 2015 • Alkermes • Indication: extended-release atypical antipsychotic for schizophrenia • Administration: IM (gluteal or deltoid muscle) once monthly – Available as 441 mg, 662 mg, 882 mg – Must continue oral aripiprazole for 21 days after receiving initial IM dose Entresto (sacubitril/valsartan) Entresto (sacubitril/valsartan) • FDA approved in July 2015 • Novartis • Indication: patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction • Administration: orally twice daily – Replaces ACE-I or ARB • Most common adverse drug reactions: hypotension, hyperkalemia 4 4/19/16 Entresto (sacubitril/valsartan) Savaysa (endoxaban) PARADIGM – HF Trial • FDA approved in January 2015 • Daiichi Sankyo Co., Ltd. • Indication: factor Xa inhibitor for… – Treatment of DVT or PE following 5-10 days parenteral anticoag – Non-valvular atrial fibrillation • Administration: orally once daily (check CrCl) • Adverse drug reactions: bleeding and anemia N Engl J Med. 2014;371(11):993-1004 PCSK9 Inhibitor Antibody Praluent (alirocumab) • FDA approved in July 2015 • Sanofi-Aventis • Indication: adjunct to diet and statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-cholesterol (LDL-C) • Administration: subcutaneously once every 2 weeks (75 mg initial, may increase to 150 mg) Praluent (alirocumab) Repatha (evolocumab) • FDA approved in August 2015 • Amgen • Indication: use in addition to diet statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or clinical atherosclerotic cardiovascular disease • Administration: subcutaneously 140 mg every 2 weeks J Clin Endocrinol Metab. 2015 Aug; 100(8): 3140–3148. 5 4/19/16 Repatha (evolocumab) Hepatitis C JAMA. 2014;311(18):1870-1883. Zepatier (elbasvir + grazoprevir) Daklinza (daclatasvir) • FDA approved January 2016 • Approved by FDA in July 2015 • Merck • Bristol-Myers Squibb • Indication: treat HCV genotypes 1 & 4, with or without ribavirin • Indication: treat HCV genotype 1 & 3 infection, • Administration: one tablet PO daily with or without with sofosbuvir (Sovaldi) food • Administration: 60 mg PO daily x 12 weeks – Duration depends on genotype, 12-16 weeks • Adverse drug reactions: fatigue, headache, • Adverse drug reactions: fatigue, headache, nausea nausea, diarrhea • Do not use in moderate-severe • Avoid use with amiodarone hepatic impairment Technivie Respiratory (ombitasvir, paritaprevir and ritonavir) • Approved by FDA in July 2015 • AbbVie • Indication: in combination with ribavirin for genotype 4 HCV without cirrhosis • Administration: 2 tablets PO qam with food x 12 weeks • Contraceptives containing ethinyl estradiol must be d/c’d prior to starting therapy 6 4/19/16 Stiolto (tiotropium + olodaterol) Stiolto (tiotropium + olodaterol) • Approved by FDA in May 2015 • Boehringer Ingelheim • Indication: maintenance treatment for COPD – Anticholenergic + LABA • Administration: 2 inhalations once daily {Respimat inhaler} • Adverse drug reactions: nasopharyngitis, cough, and back pain Eur Respir J 2015; 45: 969–979 Utibron (indacaterol/glycopyrrolate) Utibron (indacaterol/glycopyrrolate) • Approved by FDA in October 2015 • Novartis • Indication: maintenance treatment for COPD – Anticholenergic + LABA • Administration: inhale the powder contents of one capsule twice daily • Adverse drug reactions: nasopharyngitis and hypertension International Journal of COPD 2015:10 1015–1026 Miscellaneous Viberzi (eluxadoline) • Approved by FDA in May 2015 • Patheon / Forest Labs • Indication: Irritable Bowel Syndrome with Diarrhea • Administration: 100 mg PO BID – 75 mg PO BID if … • No gallbladder, cant’ tolerate 100 mg dose, mild/moderate hepatic impairment • Adverse drug reactions: constipation, nausea, abdominal pain • Contraindicated in severe hepatic impairment, alcoholism 7 4/19/16 Addyi (flibanserin) • Approved by FDA in August 2015 • Sprout Pharmaceuticals • Indication: hypoactive sexual desire disorder in premenopausal women – Works in CNS, “mechanism of action not known” • Administration: 100 mg PO daily hs {REMS} • Adverse drug reactions: dizziness, somnolence, fatigue, nausea, insomnia, dry mouth • Warning: CNS depression & hypotension Summary • Resources – http://www.centerwatch.com/drug-information/fda- approved-drugs/ – http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ DrugInnovation/ucm483775.htm • Difficult to determine acceptance and use of new drugs in practice • Impact of formularies and insurance coverage • Postmarket surveillance efforts • MedWatch: FDA reporting program [email protected] 8 .
Load more

Recommended publications
  • LGM-Pharma-Regulatory-1527671011
    Pipeline Products List Specialty Portfolio Updated Q2 2018 Updated Q2 2018 See below list of newly approved API’s, samples are readily available for your R&D requirements: Inhalation Ophthalmic Transdermal Sublingual Abaloparatide Defibrotide Sodium Liraglutide Rituximab Abciximab Deforolimus Lixisenatide Rivastigmine Aclidinium Bromide Azelastine HCl Agomelatine Alprazolam Abemaciclib Delafloxacin Lumacaftor Rivastigmine Hydrogen Tartrate Beclomethasone Dipropionate Azithromycin Amlodipine Aripiprazole Acalabrutinib Denosumab Matuzumab Rizatriptan Benzoate Budesonide Besifloxacin HCl Apomorphine Eletriptan HBr Aclidinium Bromide Desmopressin Acetate Meloxicam Rocuronium Bromide Adalimumab Difluprednate Memantine Hydrochloride Rolapitant Flunisolide Bimatoprost Clonidine Epinephrine Aflibercept Dinoprost Tromethamine Micafungin Romidepsin Fluticasone Furoate Brimonidine Tartrate Dextromethorphan Ergotamine Tartrate Agomelatine Dolasetron Mesylate Mitomycin C Romosozumab Fluticasone Propionate Bromfenac Sodium Diclofenac Levocetrizine DiHCl Albiglutide Donepezil Hydrochloride Mometasone Furoate Rotigotine Formoterol Fumarate Cyclosporine Donepezil Meclizine Alectinib Dorzolamide Hydrochloride Montelukast Sodium Rucaparib Iloprost Dexamethasone Valerate Estradiol Melatonin Alemtuzumab Doxercalciferol Moxifloxacin Hydrochloride Sacubitril Alirocumab Doxorubicin Hydrochloride Mycophenolate Mofetil Salmeterol Xinafoate Indacaterol Maleate Difluprednate Fingolimod Meloxicam Amphotericin B Dulaglutide Naldemedine Secukinumab Levalbuterol Dorzolamide
    [Show full text]
  • 2 Total Pharmaceutical Sales
    OECD Health Statistics 2021 Definitions, Sources and Methods Total pharmaceutical sales Total sales of pharmaceutical products on the domestic market, in total and by selected Anatomical Therapeutic Chemical (ATC) classification groups, based on retail prices (which means the final price paid by the customer). The ATC codes below are based on the 2021 version of the ATC Index. All alterations implemented from January 2021 are available on the WHO Collaborating Centre for Drug Statistics Methodology website at http://www.whocc.no/atc/lists_of_new_atc_ddds_and_altera/alterations_in_atc_ddd/. Note: There are at least three possible sources of under-reporting of drug sales in different countries: 1) sales data may only cover those drugs that are reimbursed by public insurance schemes; 2) they may be based on ex-factory or wholesale prices rather than retail prices; and 3) sales data may exclude drug consumption in hospitals. Data for the following countries under-estimate pharmaceutical sales reported in this section because of one of these limitations: Australia, Austria, France, Germany, Greece, Japan, Luxembourg, the Netherlands, the Slovak Republic (before 2016) and Spain. (For further information, see the country-specific information below). Please also note that depending on the allocation of pharmaceutical products with more than one use, differences in reporting of specific drugs may occur across countries, thereby affecting the relative size of specific ATC groups. Data should reflect total sales for each drug category, based on
    [Show full text]
  • Geisinger Lewistown Hospital Published: March 25, 2019
    Geisinger Lewistown Hospital Published: March 25, 2019 DESCRIPTION CHARGE Fine needle aspiration; without imaging guidance $ 607.00 Fine needle aspiration; without imaging guidance $ 286.00 Fine needle aspiration; with imaging guidance $ 2,218.00 Fine needle aspiration; with imaging guidance $ 1,691.00 Placement of soft tissue localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous, including imaging guidance; first lesion $ 1,979.00 Placement of soft tissue localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous, including imaging guidance; each $ 1,385.00 additional lesion (List separately in addition to code for primary procedure) Incision and drainage of abscess (eg, carbuncle, suppurative hidradenitis, cutaneous or subcutaneous abscess, cyst, furuncle, or paronychia); simple or single $ 657.00 Incision and drainage of abscess (eg, carbuncle, suppurative hidradenitis, cutaneous or subcutaneous abscess, cyst, furuncle, or paronychia); complicated or $ 986.00 multiple Incision and drainage of pilonidal cyst; simple $ 657.00 Incision and drainage of pilonidal cyst; complicated $ 3,726.00 Incision and removal of foreign body, subcutaneous tissues; simple $ 1,694.00 Incision and removal of foreign body, subcutaneous tissues; complicated $ 4,710.00 Incision and drainage of hematoma, seroma or fluid collection $ 3,470.00 Puncture aspiration of abscess, hematoma, bulla, or cyst $ 1,272.00 Puncture aspiration of abscess, hematoma, bulla, or cyst $ 657.00 Incision
    [Show full text]
  • ENTRESTO (Sacubitril and Valsartan) Is a Combination of a Neprilysin Inhibitor and an Angiotensin II Receptor Blocker
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Adjust adult doses every 2 to 4 weeks and pediatric doses every 2 weeks These highlights do not include all the information needed to use to the target maintenance dose, as tolerated by the patient. (2.2, 2.3) ENTRESTO safely and effectively. See full prescribing information for • Reduce starting dose to half the usually recommended starting dosage for: ENTRESTO. – patients not currently taking an ACE inhibitor or ARB or previously ENTRESTO® (sacubitril and valsartan) tablets, for oral use taking a low dose of these agents (2.5) Initial U.S. Approval: 2015 – patients with severe renal impairment (2.6) – patients with moderate hepatic impairment (2.7) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. ----------------------DOSAGE FORMS AND STRENGTHS--------------------­ • When pregnancy is detected, discontinue ENTRESTO as soon as • Film-coated tablets: 24/26 mg; 49/51 mg; 97/103 mg (3) possible. (5.1) --------------------------------CONTRAINDICATIONS----------------------------­ • Drugs that act directly on the renin-angiotensin system can cause • Hypersensitivity to any component. (4) injury and death to the developing fetus. (5.1) • History of angioedema related to previous ACEi or ARB therapy. (4) • ----------------------------RECENT MAJOR CHANGES-------------------------­ Concomitant use with ACE inhibitors. (4, 7.1) • • Indications and Usage, Adult Heart Failure (1.1) 2/2021 Concomitant use with aliskiren in patients with diabetes. (4, 7.1) ----------------------------INDICATIONS AND USAGE--------------------------­ ------------------------WARNINGS AND PRECAUTIONS----------------------­ ENTRESTO is indicated: • Observe for signs and symptoms of angioedema and hypotension. (5.2, 5.3) • to reduce the risk of cardiovascular death and hospitalization for heart • Monitor renal function and potassium in susceptible patients.
    [Show full text]
  • Minutes of PRAC Meeting on 09-12 July 2018
    6 September 2018 EMA/PRAC/576790/2018 Inspections, Human Medicines Pharmacovigilance and Committees Division Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of the meeting on 09-12 July 2018 Chair: June Raine – Vice-Chair: Almath Spooner Health and safety information In accordance with the Agency’s health and safety policy, delegates were briefed on health, safety and emergency information and procedures prior to the start of the meeting. Disclaimers Some of the information contained in the minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scope listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised. Of note, the minutes are a working document primarily designed for PRAC members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006, Rev. 1). 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018.
    [Show full text]
  • Summary of Product Characteristics 1. Name Of
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ramipril/Amlodipine Glenmark, 5 mg/5 mg, hard capsules Ramipril/Amlodipine Glenmark, 5 mg/10 mg, hard capsules Ramipril/Amlodipine Glenmark, 10 mg/5 mg, hard capsules Ramipril/Amlodipine Glenmark, 10 mg/10 mg, hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Ramipril/Amlodipine Glenmark, 5 mg/5 mg, hard capsules: each capsule contains 5 mg ramipril and amlodipine besilate equivalent to 5 mg amlodipine. Ramipril/Amlodipine Glenmark, 5 mg/10 mg, hard capsules: each capsule contains 5 mg ramipril and amlodipine besilate equivalent to 10 mg amlodipine and . Ramipril/Amlodipine Glenmark, 10 mg/5 mg, hard capsules: each capsule contains 10 mg ramipril and amlodipine besilate equivalent to5 mg amlodipine. Ramipril/Amlodipine Glenmark, 10 mg/10 mg, hard capsules: each capsule contains 10 mg ramipril and amlodipine besilate equivalent to 10 mg amlodipine . For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule Ramipril/Amlodipine Glenmark, 5 mg/5 mg, hard capsules: hard gelatin capsules with a length of 19 mm, cap: opaque pink colour, body: opaque white colour. Content of capsules: white or almost white powder. Ramipril/Amlodipine Glenmark, 5 mg/10 mg, hard capsules: hard gelatin capsules with a length of 19 mm, cap: opaque red - brown colour, body: opaque white colour. Content of capsules: white or almost white powder. Ramipril/Amlodipine Glenmark, 10 mg/5 mg, hard capsules: hard gelatin capsules with a length of 19 mm, cap: opaque dark pink colour, body: opaque white colour. Content of capsules: white or almost white powder.
    [Show full text]
  • MSM Chapter 1200 3/1/21
    MEDICAID SERVICES MANUAL TRANSMITTAL LETTER February 23, 2021 TO: CUSTODIANS OF MEDICAID SERVICES MANUAL FROM: JESSICA KEMMERER, HIPAA PRIVACY AND CIVIL RIGHTS OFFICER /Jessica Kemmerer/ BACKGROUND AND EXPLANATION The DHCFP is proposing revisions to Medicaid Services Manual (MSM), Chapter 1200 – Prescribed Drugs, Appendix A, to reflect recommendations approved on October 22, 2020, by the Drug Use Review (DUR) Board. The proposed changes include the addition of new prior authorization criteria for Doxepine Topical, the addition of new prior authorization criteria for Zeposia® (ozanimod), addition of new prior authorization for Evenity® (romosozumab-aqqg), Prolia® (denosumab), Forteo® (teriparatide) and Tymlos® (abaloparatide) within a new combined osteoporosis agents section, and addition of new prior authorization criteria for Orilissa® (elagolix) and Oriahnn® (elagolix, estradiol, and norethindrone) within a new Gonadorpin Hormone Receptor (GnRH) Antagonist and Combinations section. Additionally, the DHCFP is proposing revisions to the existing prior authorization criteria for psychotropic medications for children and adolescents, and revision to the existing clinical criteria for Epidiolex® (cannabidiol). Throughout the chapter, grammar, punctuation and capitalization changes were made, duplications removed, acronyms used and standardized, and language reworded for clarity. Renumbering and re- arranging of sections was necessary. These changes are effective March 1, 2021. MATERIAL TRANSMITTED MATERIAL SUPERSEDED MTL N/A MTL N/A MSM Ch 1200 – Prescribed Drugs MSM Ch 1200 – Prescribed Drugs Background and Explanation of Policy Changes, Manual Section Section Title Clarifications and Updates Appendix A Psychotropic Added new policy language criteria on which specific Section N Medications for drug classes may bypass polypharmacy clinical criteria. Children and Adolescents Appendix A Reserved for Future Created a new section titled “Doxepin Topical.” Added Section W Use new prior authorization criteria for doxepin topical.
    [Show full text]
  • Clinical Teach Back Cards
    Medication Safety Clinical Teach-Back Cards* The Medicare Quality Innovation Network Quality Improvement Organization (QIN-QIO) for Texas, Missouri, Oklahoma, Arkansas and Puerto Rico TMF Health Quality Institute focuses on improving lives by improving the quality of health care through contracts with federal, state and local governments, as well as private organizations. For nearly 40 years, TMF has helped health care providers and practitioners in a variety of settings improve care for their patients. *Content subject to change Medication Safety Clinical Teach-Back Cards TMF Health Quality Institute Bridgepoint I, Suite 300 5918 West Courtyard Drive Austin, TX 78730-5036 1-866-439-6863 Phone: 512-329-6610 Fax: 512-334-1775 www.tmfqin.org This material was developed by TMF Health Quality Institute, the Medicare Quality Innovation Network Quality Improvement Organization under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services. This content does not necessarily reflect CMS policy. 11SOW-QINQIO-C3.6-16-01 TEACH-BACK “I want to make sure I explained this clearly. When you get back home in a few days, what will you tell your [friend or family member] about [key point just discussed]?” Do NOT ask the patient, “Do you understand?” TEACH-BACK The “teach-back” technique is an effective method for ensuring that patients understand what you have told them. It involves asking patients to explain or demonstrate what they have been told. For example, you can say, “Please show me how you will use the asthma inhaler, so I can be sure I have given you clear instructions.” ANGIOTENSIN- CONVERTING ENZYME (ACE) INHIBITORS These drugs improve symptoms and prevent symptoms from worsening by relaxing blood vessels, controlling fluid and slowing the progression of heart failure.
    [Show full text]
  • Drugs Requiring Preauthorization
    DRUGS REQUIRING PREAUTHORIZATION The table below outlines the medications requiring a review by the Clinical Pharmacist, and if necessary, a Health Alliance Medical Director. If a provider wished for coverage of a drug designated as preauthorization required (PA), they must provide documentation to meet criteria for that particular medication. Provider must request prior authorization from Health Alliance for drugs on the following list: Drug Class Drug Name Comments ASTHMA/ COPD Advair® (fluticasone-salmeterol) See Non-Preferred ICS/LABA Combination Breo™ Ellipta® (fluticasone-vilanterol) Inhalers policy Arnuity™ Ellipta® (fluticasone- See Non-Preferred ICS Inhalers policy salmeterol) ArmonAir™ RespiClick® (fluticasone propionate) Daliresp® (roflumilast) See Daliresp policy BEHAVIORAL Dyanavel™ XR (amphetamine Member aged 6 to 12; documentation of HEALTH: suspension) inability to swallow tablets for members ADHD Quillichew® ER (methylphenidate ER) older than 12 Quillivant XR® (methylphenidate suspension) Vyvanse® chewable (lisdexamfetamine) BEHAVIORAL desvenlafaxine ER See Behavioral Health policy; HEALTH: Fetzima™ (levomilnacipran ER) two Tier 1 SSRIs and two Tier 1 SNRIs Antidepressants Khedezla™ (desvenlafaxine ER) (duloxetine and venlafaxine/venlafaxine ER) Pristiq® (desvenlafaxine) Trintellix® (vortioxetine) Viibryd® (vilazodone) BEHAVIORAL aripiprazole See Behavioral Health policy; HEALTH: Rexulti® (brexpiprazole) as adjunct therapy for Major Depressive Atypical Disorder: TWO Tier 1 SSRIs, AND TWO Tier Antipsychotics 1 SNRIs; for
    [Show full text]
  • The Evolution of Heart Failure with Reduced Ejection Fraction Pharmacotherapy: What Do We Have and Where Are We Going?
    Pharmacology & Therapeutics 178 (2017) 67–82 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate editor: M. Curtis The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going? Ahmed Selim, Ronald Zolty, Yiannis S. Chatzizisis ⁎ Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE, USA article info abstract Available online 21 March 2017 Cardiovascular diseases represent a leading cause of mortality and increased healthcare expenditure worldwide. Heart failure, which simply describes an inability of the heart to meet the body's needs, is the end point for many Keywords: other cardiovascular conditions. The last three decades have witnessed significant efforts aiming at the discovery Heart failure of treatments to improve the survival and quality of life of patients with heart failure; many were successful, Reduced ejection fraction while others failed. Given that most of the successes in treating heart failure were achieved in patients with re- Pharmacotherapy duced left ventricular ejection fraction (HFrEF), we constructed this review to look at the recent evolution of Novel drugs HFrEF pharmacotherapy. We also explore some of the ongoing clinical trials for new drugs, and investigate poten- tial treatment targets and pathways that might play a role in treating HFrEF in the future. © 2017 Elsevier Inc. All rights reserved. Contents 1. Introduction..............................................
    [Show full text]
  • New York State Medicaid Drug Utilization Board Meeting Agenda
    New York State Medicaid Drug Utilization Board Meeting Agenda The Drug Utilization Review (DUR) Board will meet September 15, 2016, from 9:00 a.m. to 4:00 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York Agenda Items A. Preferred Drug Program (PDP) Reviews The DUR Board will review therapeutic classes listed below, as they pertain to the PDP. The DUR Board will review clinical and financial information, to recommend preferred and non-preferred drugs. For therapeutic classes currently subject to the PDP, the DUR Board will only consider clinical information which is new since the previous review of the therapeutic class and then consider financial information. New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials (comparative evidence is preferred, or placebo controlled when no head-to-head trials are available). Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of review and submission is discouraged. Those wishing to submit clinical information must do so in an electronic format by September 1, 2016 or the DUR Board may not have ample time to review the information. 1. Hepatitis C Agents – Direct Acting Antivirals (Previous review date: April 27, 2016) Copegus (ribavirin), Daklinza (daclatasvir), Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Moderiba (ribavirin), Olysio (simeprevir), Rebetol (ribavirin), Ribasphere (ribavirin), ribavirin,
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]